Cargando…
Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
Addition of induction chemotherapy (IC) to concurrent chemoradiotherapy (CC) is an encouraging first-line treatment strategy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We evaluated the clinical efficacy and toxicity of addition of gemcitabine plus cisplatin (GP) IC to...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722524/ https://www.ncbi.nlm.nih.gov/pubmed/29228572 http://dx.doi.org/10.18632/oncotarget.18245 |
_version_ | 1783285031928594432 |
---|---|
author | Fangzheng, Wang Quanquan, Sun Chuner, Jiang Lei, Wang Fengqin, Yan Zhimin, Ye Tongxin, Liu Min, Xu Peng, Wu Haitao, Jiang Aizawa, Rihito Sakamoto, Masoto Yuezhen, Wang Zhenfu, Fu |
author_facet | Fangzheng, Wang Quanquan, Sun Chuner, Jiang Lei, Wang Fengqin, Yan Zhimin, Ye Tongxin, Liu Min, Xu Peng, Wu Haitao, Jiang Aizawa, Rihito Sakamoto, Masoto Yuezhen, Wang Zhenfu, Fu |
author_sort | Fangzheng, Wang |
collection | PubMed |
description | Addition of induction chemotherapy (IC) to concurrent chemoradiotherapy (CC) is an encouraging first-line treatment strategy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We evaluated the clinical efficacy and toxicity of addition of gemcitabine plus cisplatin (GP) IC to intensity-modulated radiotherapy (IMRT) and CC for patients with locoregionally advanced NPC. At a median follow-up duration of 48 months (10–59 months), 4-year local relapse-free survival (LRFS) was 86.9%, regional relapse-free survival (RRFS) was 90.6%, distant metastasis-free survival (DMFS) was 79.8%, progression-free survival (PFS) was 77.0%, and overall survival (OS) was 81.9%. Univariate analysis revealed that T stage, N stage, clinical stage, and CC correlated with OS, while N stage and clinical stage correlated with PFS. In multivariate analysis, T4 was a prognostic indicator of poor OS and PFS, and N3 was a prognostic indicator of poor OS. Having received ≥ 2 cycles of IC was prognostic of better RRFS. During IC, grade 3–4 thrombocytopenia occurred in 10 patients, and grade 3–4 leukocytopenia was observed in 16 patients. Two patients developed mild liver dysfunction. These findings indicate that GP-based IC followed by CC has promising efficacy with acceptable toxicities. |
format | Online Article Text |
id | pubmed-5722524 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57225242017-12-10 Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma Fangzheng, Wang Quanquan, Sun Chuner, Jiang Lei, Wang Fengqin, Yan Zhimin, Ye Tongxin, Liu Min, Xu Peng, Wu Haitao, Jiang Aizawa, Rihito Sakamoto, Masoto Yuezhen, Wang Zhenfu, Fu Oncotarget Research Paper Addition of induction chemotherapy (IC) to concurrent chemoradiotherapy (CC) is an encouraging first-line treatment strategy for patients with locoregionally advanced nasopharyngeal carcinoma (NPC). We evaluated the clinical efficacy and toxicity of addition of gemcitabine plus cisplatin (GP) IC to intensity-modulated radiotherapy (IMRT) and CC for patients with locoregionally advanced NPC. At a median follow-up duration of 48 months (10–59 months), 4-year local relapse-free survival (LRFS) was 86.9%, regional relapse-free survival (RRFS) was 90.6%, distant metastasis-free survival (DMFS) was 79.8%, progression-free survival (PFS) was 77.0%, and overall survival (OS) was 81.9%. Univariate analysis revealed that T stage, N stage, clinical stage, and CC correlated with OS, while N stage and clinical stage correlated with PFS. In multivariate analysis, T4 was a prognostic indicator of poor OS and PFS, and N3 was a prognostic indicator of poor OS. Having received ≥ 2 cycles of IC was prognostic of better RRFS. During IC, grade 3–4 thrombocytopenia occurred in 10 patients, and grade 3–4 leukocytopenia was observed in 16 patients. Two patients developed mild liver dysfunction. These findings indicate that GP-based IC followed by CC has promising efficacy with acceptable toxicities. Impact Journals LLC 2017-05-27 /pmc/articles/PMC5722524/ /pubmed/29228572 http://dx.doi.org/10.18632/oncotarget.18245 Text en Copyright: © 2017 Fangzheng et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper Fangzheng, Wang Quanquan, Sun Chuner, Jiang Lei, Wang Fengqin, Yan Zhimin, Ye Tongxin, Liu Min, Xu Peng, Wu Haitao, Jiang Aizawa, Rihito Sakamoto, Masoto Yuezhen, Wang Zhenfu, Fu Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title | Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title_full | Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title_fullStr | Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title_full_unstemmed | Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title_short | Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
title_sort | gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5722524/ https://www.ncbi.nlm.nih.gov/pubmed/29228572 http://dx.doi.org/10.18632/oncotarget.18245 |
work_keys_str_mv | AT fangzhengwang gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT quanquansun gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT chunerjiang gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT leiwang gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT fengqinyan gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT zhiminye gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT tongxinliu gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT minxu gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT pengwu gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT haitaojiang gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT aizawarihito gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT sakamotomasoto gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT yuezhenwang gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma AT zhenfufu gemcitabinecisplatininductionchemotherapybeforeconcurrentchemotherapyandintensitymodulatedradiotherapyimprovesoutcomesforlocoregionallyadvancednasopharyngealcarcinoma |